Want to see PTKFY full AI Analyst Report?
Top Page
PT Kalbe Farma Tbk
(OTC:PTKFY)
Select Model
Select Model
Rating:77Outperform
Price Target:
$9.00
â–²(15.98% Upside)
Action:Reiterated
Date:08/06/26
The score is driven primarily by strong financial performance—especially a very low-leverage balance sheet and solid profitability—combined with attractive valuation (low P/E and a supportive dividend). Offsetting these positives, technicals suggest the stock is still in a longer-term downtrend despite some near-term strength, which tempers the overall rating.
Positive Factors
Very low leverage
The exceptionally low debt burden gives Kalbe Farma substantial financial flexibility and reduces exposure to refinancing and interest-cost pressure. This supports continued investment in products and distribution while helping the company remain resilient if operating conditions weaken.
Negative Factors
Margin compression
Although profitability remains solid, the downward movement in gross, net, EBIT, and EBITDA margins indicates that earlier profitability levels are not being fully maintained. If this trend persists, it could constrain earnings growth even while revenue continues to expand.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
The exceptionally low debt burden gives Kalbe Farma substantial financial flexibility and reduces exposure to refinancing and interest-cost pressure. This supports continued investment in products and distribution while helping the company remain resilient if operating conditions weaken.
Read all positive factors
PT Kalbe Farma Tbk (PTKFY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.88B
Dividend Yield2.48%
Average Volume (3M)510.00
Price to Earnings (P/E)9.2
Beta (1Y)0.62
Revenue Growth7.85%
EPS Growth2.38%
CountryUS
Employees12,835
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)16084.00
Shares Outstanding234,066,960
10 Day Avg. Volume0
30 Day Avg. Volume510
Financial Highlights & Ratios
PEG Ratio0.91
Price to Book (P/B)2.19
Price to Sales (P/S)1.45
P/FCF Ratio20.78
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PT Kalbe Farma Tbk Business Overview & Revenue Model
Company Description
PT Kalbe Farma Tbk is engaged in the development, distribution, and trading of pharmaceutical products. It operates through the following divisions: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution and Logistic. The Pre...
PT Kalbe Farma Tbk Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
73
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 37.91T | 35.32T | 32.63T | 30.45T | 28.93T | 26.26T |
| Gross Profit | 14.12T | 14.06T | 12.96T | 11.82T | 11.70T | 11.28T |
| EBITDA | 5.50T | 5.60T | 5.08T | 4.41T | 5.25T | 4.87T |
| Net Income | 3.63T | 3.66T | 3.24T | 2.77T | 3.38T | 3.18T |
Balance Sheet | ||||||
| Total Assets | 33.21T | 30.70T | 29.43T | 27.06T | 27.24T | 25.67T |
| Cash, Cash Equivalents and Short-Term Investments | 5.01T | 4.49T | 4.87T | 3.40T | 4.10T | 6.48T |
| Total Debt | 829.84B | 297.28B | 559.22B | 618.54B | 1.17T | 626.16B |
| Total Liabilities | 7.34T | 5.97T | 4.84T | 3.94T | 5.14T | 4.40T |
| Stockholders Equity | 24.43T | 23.31T | 22.79T | 21.42T | 20.39T | 19.58T |
Cash Flow | ||||||
| Free Cash Flow | 2.50T | 2.46T | 3.53T | 1.73T | 2.90T | 1.83T |
| Operating Cash Flow | 3.39T | 3.27T | 4.79T | 2.91T | 3.77T | 2.83T |
| Investing Cash Flow | -1.25T | -799.89B | -1.25T | -1.14T | -1.37T | -1.06T |
| Financing Cash Flow | -1.17T | -2.87T | -2.09T | -2.44T | -2.41T | -745.18B |
PT Kalbe Farma Tbk Technical Analysis
Negative
7.76
Price Trends
8.45
Negative
8.40
Negative
9.83
Negative
Market Momentum
-0.15
Positive
44.60
Neutral
70.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTKFY, the sentiment is Negative. The current price of 7.76 is below the 20-day moving average (MA) of 8.18, below the 50-day MA of 8.45, and below the 200-day MA of 9.83, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 44.60 is Neutral, neither overbought nor oversold. The STOCH value of 70.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PTKFY.
PT Kalbe Farma Tbk Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $1.88B | 9.17 | 15.21% | 2.48% | 7.85% | 2.38% | |
71 Outperform | $107.18B | 24.39 | 5.52% | 5.46% | 23.68% | -30.90% | |
68 Neutral | $657.68B | 41.42 | 19.55% | 1.93% | 7.81% | -35.95% | |
67 Neutral | $99.63B | 17.18 | 24.64% | 3.67% | 6.93% | -18.14% | |
66 Neutral | $173.95B | 40.33 | 4.89% | 5.64% | -0.21% | -59.71% | |
53 Neutral | $3.63B | 17.52 | 23.44% | 0.58% | -2.45% | -70.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
PTKFY
PT Kalbe Farma Tbk
8.06
-7.02
-46.57%
GSK
GlaxoSmithKline
49.51
4.23
9.34%
JNJ
Johnson & Johnson
273.20
88.49
47.91%
PFE
Pfizer
30.52
7.49
32.50%
SNY
Sanofi
44.34
-4.30
-8.84%
OGN
Organon
13.84
7.15
106.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.